Antibody-drug Conjugates

Antibody-Drug Conjugates in Cancer Therapy: Innovations, Challenges, and Future Directions

by
Antibody-Drug Conjugates in Cancer Therapy: Innovations, Challenges, and Future Directions

Antibody-drug conjugates (ADCs) have emerged as a promising approach for cancer treatment, garnering significant attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drug molecules, they enhance the therapeutic index, selectively targeting cancer cells while minimizing systemic toxicity. However, several challenges remain: including the selection of appropriate target antigens, enhancing antibodies, … Read more

Unveiling the Potential of Antibody-Drug Conjugates

by
Unveiling the Potential of Antibody-Drug Conjugates

This article, “Unveiling the Potential of Antibody-Drug Conjugates,” is an excellent industry review that provides a panoramic view of the hot field of Antibody-Drug Conjugates (ADCs). Next, we will journey from history to the future, delving into molecular mechanisms and clinical practices, connecting textbook knowledge to cutting-edge research. A Precision Guided “Trojan Horse”: An In-Depth … Read more

Review Considerations for Antibody-Drug Conjugates (ADC) Pharmaceutical Research

by
Review Considerations for Antibody-Drug Conjugates (ADC) Pharmaceutical Research

This page’s PPT lacks a guiding principle, which is as follows: four guiding principles: Article information source from the WeChat public account Pharmacology Talk *This WeChat public account maintains neutrality regarding all original and reprinted content, statements, and opinions. The content is for public sharing only. If any reprinted works or images have incorrect author … Read more

ADC: Where It Comes From and Where It Is Going?

by
ADC: Where It Comes From and Where It Is Going?

ADC, or antibody-drug conjugates, is a term that everyone is likely familiar with. The design concept of ADC originated from Paul Ehrlich’s idea of “magic bullets,” aimed at achieving precise targeted therapy while minimizing damage to normal tissues. As of now, there are 15 ADC drugs approved for market worldwide, with over 400 ADC candidates … Read more

Zymeworks: Overview of Leading ADC Platforms

by
Zymeworks: Overview of Leading ADC Platforms

Antibody-drug conjugates (ADCs) are a class of biotherapeutic drugs targeting cancer, combining the targeting capability of monoclonal antibodies (mAbs) with the anticancer efficacy of cytotoxic drugs (Payload). The antibody and payload are linked by a linker, allowing specific drugs to be delivered to cancer cells targeted by the antibody. Once inside the cell, the linked … Read more

Key Considerations in ADC Design Based on Pharmacokinetics

by
Key Considerations in ADC Design Based on Pharmacokinetics

Please click the “Bio New Thinking” above to follow for more exciting content! Introduction With the continuous improvement of biopharmaceutical research and clinical research levels, the research and application of Antibody-Drug Conjugates (ADCs) have been increasing. ADCs are mainly composed of antibodies, linkers, and small molecule toxins, combining high targeting specificity with high cytotoxicity. However, … Read more

Another Bright Path for ADC Development – Non-Internalizing ADC

by
Another Bright Path for ADC Development - Non-Internalizing ADC

Antibody-Drug Conjugates (ADC) typically require internalization to release their cytotoxic payload. However, there are strict limitations, requiring high expression of internalizing antigens and efficient intracellular processing. A new method has emerged, allowing the payload to be released extracellularly from cleavable linkers after binding to poorly internalizing antigens or other tumor components. This method eliminates the … Read more

Analysis Method Development for ADC Drugs

by

Antibody-drug conjugates (ADCs) are primarily composed of three “modules”: an antibody (usually a monoclonal antibody), a linker, and a cytotoxic drug (payload). In recent years, ADCs have stood out among biological drugs due to their combination of the potent killing effect of chemotherapy agents and the precise targeting of antibody drugs, earning the title of … Read more

Key Points and Challenges in PK/PD Studies of ADC Drugs

by
Key Points and Challenges in PK/PD Studies of ADC Drugs

Click the blue text above to follow us IntroductionAntibody-drug conjugates (ADC) consist of antibodies, linkers, and small molecule toxins. While they possess the advantages of high targeting ability and high cytotoxicity, their structural diversity and complexity, as well as the low levels of small molecule toxins released in the circulatory system, present numerous challenges for … Read more

Innovative Delivery: Comprehensive Analysis of ‘Magic Bullet’ ADC Drug Screening

by
Innovative Delivery: Comprehensive Analysis of 'Magic Bullet' ADC Drug Screening

Authors: Li Jiaxing, Hu Linghong, Hu YuhaoImages: Yang Zhenzhen1. Summary Antibody-drug conjugates (ADCs) rejuvenate the concept of targeted chemotherapy by coupling cytotoxic payloads to antibodies. The first stage of the complex intracellular toxin delivery process of ADCs is endocytosis. Analyzing the endocytosis of target receptors and ADCs can greatly enhance preclinical studies, clinical translation, and … Read more